Cargando…

Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid

Detalles Bibliográficos
Autores principales:	Wang, Yu, Chen, Xubo, Xiao, Wenying, Zhao, Danyang, Feng, Liuliu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389848/ https://www.ncbi.nlm.nih.gov/pubmed/35995309 http://dx.doi.org/10.1016/j.jinf.2022.08.012

Ejemplares similares

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
por: Periyasamy, P., et al.
Publicado: (2023)

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
por: Wang, Lindsey, et al.
Publicado: (2022)

Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023)

COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
por: Alshanqeeti, Shatha, et al.
Publicado: (2022)

Efficacy of Paxlovid in patients with acute kidney injury who developed COVID-19
por: Cai, Hong, et al.
Publicado: (2022)

Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients
por: Zhao, Deze, et al.
Publicado: (2023)

Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature
por: Yang, Da‐Wei, et al.
Publicado: (2023)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Post COVID-19 Acute Myocardial Infarction Rebound
por: Fardman, Alexander, et al.
Publicado: (2020)

Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023)

The future of Paxlovid for COVID-19
por: Burki, Talha
Publicado: (2022)

Projected COVID-19 Mortality Reduction From Paxlovid Rollout
por: Khunte, Mihir, et al.
Publicado: (2023)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

COVID-19 Pandemic and Possible Rebound Phenomenon in Incidence of Acute Myocardial Infarction
por: Čulić, Viktor, et al.
Publicado: (2021)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

Mathematical model of SARS-CoV-2 immunity predicts Paxlovid rebound
por: Ranard, Benjamin L., et al.
Publicado: (2023)

Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China
por: Zhang, Weina, et al.
Publicado: (2023)

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?
por: Gousseff, Marie, et al.
Publicado: (2020)

A five-day course of ivermectin may reduce the duration of COVID-19 illness
por: Ahmed, Sabeena, et al.
Publicado: (2021)

COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
por: Wang, Lindsey, et al.
Publicado: (2022)

Reply to Čulić et al—COVID-19 Pandemic and Possible Rebound Phenomenon in Incidence of Acute Myocardial Infarction
por: Fardman, Alexander, et al.
Publicado: (2021)

Relapse in the first 8 weeks after onset of COVID-19 disease in outpatients: Viral reactivation or inflammatory rebound?
por: Buskermolen, Maaike, et al.
Publicado: (2021)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

Neurological complications during the course of severe COVID-19: is it just the tip of the iceberg?
por: Yamanyar, Gulcin Koc, et al.
Publicado: (2022)

The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants
por: Wang, Yu, et al.
Publicado: (2023)

Paxlovid for hospitalized COVID-19 patients with chronic kidney disease
por: Cai, Hong, et al.
Publicado: (2023)

Efficacy of Paxlovid and Lagevrio for COVID-19 Infection in Patients With Inflammatory Bowel Disease: A Propensity-Matched Study
por: Hashash, Jana G., et al.
Publicado: (2023)

Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
por: Zhang, Liulu, et al.
Publicado: (2022)

Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2021)

Impact of COVID-19 on psychiatric day care services
por: Koreki, Akihiro, et al.
Publicado: (2020)

Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2022)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2023)

The public health impact of Paxlovid COVID-19 treatment in the United States
por: Bai, Yuan, et al.
Publicado: (2023)

Paxlovid-Tacrolimus Drug–Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19
por: Berar Yanay, Noa, et al.
Publicado: (2022)

In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
por: Lavie, Carl J.
Publicado: (2021)

Is Vitamin D One of the Key Elements in COVID-19 Days?
por: Aslan, M. T., et al.
Publicado: (2020)

Clinical course of severe and critically ill patients with coronavirus disease 2019 (COVID-19): A comparative study
por: Chen, Luyan, et al.
Publicado: (2020)

Does type of immunosupression influence the course of Covid-19 infection?
por: Razanamahery, J., et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rkjr1nd3pi82pk1agc7o88pl08